drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A bispecific T‑cell engager (BiTE) antibody construct linking CD3 on T cells to CD19 on B‑cell ALL blasts to drive T‑cell–mediated cytotoxicity and MRD clearance.
nci_thesaurus_concept_id
C62528
nci_thesaurus_preferred_term
Blinatumomab
nci_thesaurus_definition
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.
drug_mesh_term
Blinatumomab
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
A bispecific T‑cell engager that binds CD19 on B‑cell blasts and CD3 on T cells, forming an immunologic synapse that activates and redirects T cells to kill CD19+ cells via perforin/granzyme‑mediated cytotoxicity, leading to clearance of minimal residual disease.
drug_name
Blinatumomab
nct_id_drug_ref
NCT06507514